Home / Market News / $ENSC

$ENSC news and market catalysts

The 9 most recent market catalysts affecting $ENSC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 0 high impact 4 bullish 0 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Bullish Impact 75
Ensysce Biosciences Reports Third Quarter 2026 Financial and Operational Results
Ensysce Biosciences reported its Q3 2026 financial and operational results. The company's cash position significantly improved to $29.7 million from $4.3 million, which is a positi…
Nov 13, 2026 Corporate Catalyst Neutral Impact 65
UBS Initiates Coverage on Ensysce Biosciences With Buy Rating
UBS initiated coverage on Ensysce Biosciences (ENSC) with a 'Buy' rating and a $2.00 price target. This analyst action is significant as it provides a new, positive institutional e…
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Ensysce Biosciences Announces CEO Transition
Ensysce Biosciences is undergoing a planned leadership transition. Lynn Kirkpatrick, who has served as CEO since 2009, will transition to COO, and President James Morrisson will be…
Oct 20, 2026 Corporate Catalyst Neutral Impact 65
Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2
Cantor Fitzgerald analyst Olivia Brayer Saunders initiated coverage on Ensysce Biosciences (ENSC) with an Overweight rating and a $2 price target. This event is significant as it i…
Aug 14, 2026 Corporate Catalyst Neutral Impact 55
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $8.25 Price Valuation
The headline's primary impact is on Ensysce Biosciences (ENSC) due to the specific price valuation. While a positive valuation from a research firm is generally bullish, Zacks Smal…
Aug 4, 2026 Corporate Catalyst Bullish Impact 75
Ensysce Biosciences shares are trading higher after the company received a U.S. patent notice titled "compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof."
This patent notice is a significant corporate catalyst for Ensysce Biosciences, as it strengthens their intellectual property portfolio in a potentially lucrative area. The 'compos…
Aug 3, 2026 Corporate Catalyst Bullish Impact 65
12 Health Care Stocks Moving In Monday's After-Market Session
The filing reports after-market trading activity for 12 healthcare stocks, highlighting both gainers and losers. For companies like Inspire Medical Systems (INSP), ClearPoint Neuro…
Aug 3, 2026 Corporate Catalyst Bullish Impact 75
Ensysce Biosciences shares are trading higher after the company received a notice of allowance for a U.S. patent titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF"
The patent allowance for 'COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF' is a significant positive catalyst for Ensysce Biosciences (ENSC). T…
Aug 3, 2026 Corporate Catalyst Neutral Impact 65
Ensysce Biosciences Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF".
Ensysce Biosciences announced a Notice of Allowance for a U.S. patent covering 'COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF'. This is a pos…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.